Myriad Genetics Inc (MYGN.OQ)

MYGN.OQ on NASDAQ Stock Exchange Global Select Market

1 May 2015
Change (% chg)

-- (--)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for MYGN.OQ


Myriad Genetics, Inc. (Myriad) is a molecular diagnostic company. The Company is focused on developing and marketing predictive medicine, personalized medicine and prognostic medicine tests. It performs all of its molecular diagnostic testing and analysis in its own reference laboratories. These technologies include the... (more)


Beta: 0.79
Market Cap(Mil.): $2,384.60
Shares Outstanding(Mil.): 71.12
Dividend: --
Yield (%): --


  MYGN.OQ Industry Sector
P/E (TTM): 23.22 37.21 40.23
EPS (TTM): 1.44 -- --
ROI: 15.65 6.96 15.26
ROE: 16.12 11.10 16.08
Search Stocks

Myriad, Quest settle dispute over genetic cancer test

- Quest Diagnostics and Myriad Genetics have settled their patent dispute over genetic testing technology used to detect breast cancer.

09 Feb 2015

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Wright Reports
Provider: Stock Traders Daily
Provider: S&P Capital IQ Factual Report
Provider: Reuters Investment Profile
Provider: Thomson Reuters Stock Report

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks